Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Current Deferred Revenue (2018 - 2025)

TransMedics (TMDX) has 8 years of Current Deferred Revenue data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 66.76% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, up 66.76%, while the annual FY2025 figure was $2.9 million, 66.76% up from the prior year.
  • Current Deferred Revenue reached $2.9 million in Q4 2025 per TMDX's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.3 million in Q3 2025 and bottomed at $105000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $1.2 million, with a median of $960000.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: tumbled 88.72% in 2021, then soared 1063.27% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $250000.0 in 2021, then dropped by 3.6% to $241000.0 in 2022, then soared by 713.69% to $2.0 million in 2023, then fell by 11.17% to $1.7 million in 2024, then soared by 66.76% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $2.9 million in Q4 2025, $3.3 million in Q3 2025, and $1.6 million in Q2 2025.